Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital in San Diego, shared the implications of the findings from INTEGUMENT-PED, the phase 3 study assessing the efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients with atopic dermatitis (AD), for future clinical practice.
This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology.
At the 2024 American Academy of Dermatology Annual Meeting, Lawrence Eichenfield, MD, chief of pediatric dermatology at Rady Children's Hospital in San Diego and professor of dermatology and pediatrics at the University of California, San Diego, presented late-breaking findings from the INTEGUMENT-PED phase 3 randomized controlled trial of roflumilast cream 0.05% in children 2 to 5 years of age with atopic dermatitis (AD).
In an interview with AJMC, Eichenfield said that roflumilast cream 0.05% had positive results in pediatric patients with AD in terms of efficacy and safety. He noted that he is looking forward to roflumilast cream being "hopefully approved" and "potentially having this in our armamentarium for treating young children."
Transcript
How do the results of the INTEGUMENT-PED study contribute to our understanding of AD treatment options for young children? What implications might they have for clinical practice and future research?
First, to go through some of the basics, the study hit the sort of standard outcome measures that we look for. What percentage of patients made it to clear or almost cleared? About 25% of those were within a 4-week time period with once-a-day application with a big delta, or almost 15% delta, between the vehicle.
It was very interesting to me that a lot of the population that got that clear, or almost clear, were already clear or almost clear by 2 weeks, and there was almost 80 something percent of those because it was 21% of the patients made clear or almost clear at week 2.
The secondary outcome measures being clear or almost clear at EASI [Eczema Area and Severity Index] 75, and the percentage of patients who had at least a 4-part drop in itch as compared to their baseline was consistent with a nice separation from the vehicle cream throughout the course of the study.
When we looked very early, the improvement in the itch with roflumilast was seen as early as 24 hours after the first application. So, it was a very rapid separation of itch scores from the vehicle.
Overall, I think having this move forward and hopefully be approved as a new nonsteroidal, which is very well formulated, can be helpful in our care of patients with atopic dermatitis. We show in this case that it helped to improve eczema in 2- to 5-year-olds with early clinical responses and very good tolerance levels. So, we look forward to potentially having this in our armamentarium for treating young children.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen